Conditions: Dyslipidemia
Keywords: Dyslipidemias Mixed dyslipidemia Hypercholesterolemia Atherosclerosis Atorvastatin Simvastatin Rosuvastatin Metabolic Diseases Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents Cholesteryl Ester Transfer Protein Inhibitors Cholesteryl Ester Lipid Metabolism Disorders
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 398
Healthy volunteers: no

Brief summary:
The primary purpose of your participation in this study is to help answer the following research question(s)

* Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile more than statins alone.
* Whether LY2484595 alone improves blood fats profile compared to sugar pills.
* Whether LY2484595 interferes with break down or functioning of statins.
* Whether LY2484595 has any side effects that would not support testing it in future studies.

Detailed description:
Patients will be stratified according to baseline levels of serum triglycerides (\<150 or greater than or equal to 150 milligram/deciliter (mg/dL), HDL-C (\<45 or greater than or equal to 45 mg/dL for men; \<50 or greater than or equal to 50 mg/dL for women), and region (United States or Europe). After a diet lead-in and prior therapy washout phase, subjects meeting all entry criteria will be randomized to one of 10 double-blind treatment groups for a 12 week treatment phase. After randomization, patients will self-administer the study drugs once a day with a low fat meal as their first meal of the day.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None arm 8: None arm 9: None arm 10: None

Interventions: intervention 1: LY2484595 intervention 2: Atorvastatin intervention 3: Simvastatin intervention 4: Rosuvastatin intervention 5: Placebo for LY2484595 intervention 6: Placebo for Statins
Intervention descriptions: intervention 1: Administered daily by mouth for 12 weeks intervention 2: Administered daily by mouth for 12 weeks intervention 3: Administered daily by mouth for 12 weeks intervention 4: Administered daily by mouth for 12 weeks intervention 5: Administered daily by mouth for 12 weeks intervention 6: Administered daily by mouth for 12 weeks

Protocol document: